Sera Prognostics (NASDAQ: SERA) has announced the appointment of Tiffany Inglis, MD, FACOG, as chief medical officer (CMO).
Dr. Inglis brings extensive clinical leadership expertise to Sera. As CMO, she will lead clinical operations to establish Sera as a leader in women’s health diagnostics to improve the health of pregnant women and newborns.
In a statement, Zhenya Lindgardt, CEO of Sera, commented, “As an OBGYN, Dr. Inglis understands the importance of delivering real-time, actionable information to patients that can achieve healthier outcomes for both mom and baby. The intersection of her clinical expertise and her more recent tenure as CMO and Medical Director across major payer networks makes her the perfect fit for Sera during a pivotal time, as we prepare for publication of the PRIME study and launch pilots with state Medicaid programs with our breakthrough PreTRIM Test.”
Dr. Inglis remarked, “I’ve dedicated my career to improving outcomes for mothers and babies, and I’m thrilled to join Sera to continue this work. Sera has an incredible opportunity to transform the maternal and neonatal care landscape to be more proactive, personalized and accessible for women to ultimately make the best decisions about their health. I look forward to collaborating on the organization’s leading innovation to drive greater awareness around pre-term birth to deliver meaningful clinical outcomes for women and babies.”
